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ABSTRACT
Spasticity is an entity with which physical therapists are quite frequently
faced. It is a common phenomenon among individuals who have sustained
central nervous system damage. Spasticity is "associated with a wide variety of
neurological diagnoses and may have benefits as well as negative qualities.
The negative effects can lead to multiple complications which interfere with
functions of every day living. Management of spasticity becomes necessary
when it ~causes complication.s or interferes with function. There are several
modes of intervention, including conservative physical therapy approaches
and/or medical approaches.
The purpose of this independent study is to review two medical methods of
intervention: pharmacological treatment and dorsal rhizotomy.
Pharmacological treatments include medications or local injections of various
agents. These treatments only provide temporary relief unless they are
conlLnued and/or repeated. Although pharmacological treatments have been
found to be effective to reduce spasticity, they may have unwanted side effects.

Dors~1 rhizotomies have been successful for reducing spasticity in appropriate
\

."

candidates. The effects of this treatment are permanent and irreversible. Side

VJ.J.

effects are often temporary, such as sensory loss or muscle weakness, and
there are risks related to surgery and anaesthesia.
1\
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CHAPTER 1
INTRODUCTION
Spasticity is a common phenomenon among individuals who have
sustained some type of insult to the central nervous system (CNS). It is
associated with a wide variety of neurological diagnoses. A few examples are:
cerebrovascular accident (CVA), cerebral palsy(CP), traumatic brain injury
(TBI), and spinal cord injury (SCI). Resulting from an upper motor neuron
lesion,1 spasticity is defined as the hyperexcitability of the spinal stretch reflex
resulting in a velocity-dependent increase in the tonic stretch reflex with
exaggerated tendon jerks. 2

,.

Spasticity has both desirable and undesirabie effects. For example, it
can be an asset to an individual as a means for movement. By the same
token, it can become a problem if it is too severe and interferes with movement.
The undesirable qualities of spasticity can lead to secondary physical
complications. Consequently, it becomes necessary to control unwanted
spasticity in an attempt to allow the individual his or her fullest potential for
rehabilitation.
Intervention and management of spasticity can take a variety of forms. It
can include conservative, medical, or surgical techniques. Which type is used
will be affected by each individual's particular needs and problems. Treatment
1

2

is driven by symptoms because, in the majority of cases, the underlying cause
cannot be treated or reversed (Le., traumatic brain injury).3
The purpose of this independent study is to explore current literature and
to discuss two medical approaches for the management of spasticity. This
review will include an examination of spasticity, a discussion of pharmacological
therapy, and a discussion of dorsal rhizotomy.

CHAPTER 2
SPASTICITY
Spasticity is often encountered in individuals who have sustained some
type of insult to the CNS. More specifically, the lesion can be either to the
brain or spinal cord. 3 It is important to note that this spasticity stems from an
upper motor neuron lesion,4 such as would result with injury or pathology to the
brain or spinal cord.
There are a variety of neurological diagnoses in which spasticity manifests
itself. These include traumatic brain and spinal cord injury, multiple sclerosis,
cerebrovascular accident, cerebral palsy, and some rare degenerative
processes of the CNS. 1,3,5
Clinically, there are a variety of other phenomena which are related to
spasticity. These phenomena vary somewhat depending upon whether it is a
cerebral lesion or an insult to the spinal cord. 6 Spinal cord lesions present with
flexor patterns in the lower extremities, early flexor spasms, clasp-knife
phenomenon, clonus, spinal shock for 1-16 weeks, exaggerated exteroceptive
reflexes, and autonomic dysreflexia. 6 Cerebral lesions present with tone
predominant in antigravity muscles, rare flexor spasms, less clasp-knife
phenomenon, less clonus, cerebral shock for two to three weeks, absence of

3

4

superficial abdominal and cremasteric reflexes', absent autonomic phenomena. 6
Samkoff states that when damage to the CNS occurs, it leads to a
disconnection of the lower motor neuron from the control of upper motor
neurons of the brain, brainstem, and spinal cord. Spasticity is only one
manifestation of an upper motor neuron lesion, and there are associated
positive signs such as the Babinski response, hyperactive nociceptor reflexes,
flexor and extensor spasms, and dystonia. Weakness and loss of dexterity are
negative signs.
Considering the various neurological diagnoses and their site of insult, it
becomes evident that the clinical picture of spasticity will vary from patient to
patient. For example, consider the differences between an individual with
multiple sclerosis and an individual who has sustained a CVA. Multiple
sclerosis is a progressive degenerative disease in which spasticity may stem
from the involvement of multiple sites 8 ; thus, spasticity could present in more
than one area of the body simultaneously. An individual who has sustained a
CVA typically has had an insult of cerebral origin, with deficits occurring on the
side of the body opposite to the site of the lesion. 1 This example demonstrates
how the physical manifestation of spasticity varies with diagnosis and the
specific location of the lesion.
A closer examination of the definition of. spasticity becomes necessary to
truly gain a better knowledge of this complex phenomenon. Lance2 describes
spasticity as the hyperexcitability of the spinal stretch reflex resulting in a
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velocity-dependent increase in the tonic stretch reflex with exaggerated tendon
jerks. Lance proposed this definition in 1980, and it is now widely accepted as
the definition of spasticity by most clinicians and physiologists. 9
Young and Wiegner10 stated that "spastic patients may be more
handicapped by reduction in reciprocal inhibition than by hyperexcitability of the
stretch reflex." Pierrot-Deseilligny11 suggests that motor disability comes from
the triggering of a stretch reflex in antagonistic muscles during active
movement. An exaggeratio.n of the stretch reflex or a malfunction of reciprocal
la inhibition are both means by which this could happen.
Although there are different opinions about the underlying cause of
spasticity, a similarity does exist: involvement of the stretch reflex and
reciprocal inhibition.
The stretch reflex begins when extrafusal (skeletal) muscle fibers are
stretched, resulting in increased activity in the alpha motor neurons of the
agonist muscle, causing it to contract. The afferent limb of the reflex consists
of the type la and II afferents which run from the muscle spindle, enter the
spinal cord, and then synapse with the alpha motor neurons of the agonist
muscle. The la afferents also synapse with inhibitory interneurons to the
antagonist preventing contraction (reciprocal inhibition). The stretch reflex can
be evoked by a dynamic stretch, such as tapping the tendon, or by a static
stretch. In this pathway is another interneuron called the Renshaw cell. It is
stimulated each time the alpha motor neuron is activated. This activation
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causes inhibition of the same motor neuron which activated it. It is believed
that the Renshaw cell diminishes the activity of the alpha motor neuron to
prevent oscillation or, in other words, continuous reflex action. 12
As physical therapists work with neurological patients, the role of
spasticity becomes an important issue. Spasticity can be beneficial or
problematic. Spasticity may be welcomed for the following reasons: bowel
training, hemiplegic gait, increased muscle bulk; reduced risk of osteopenia. 13
Spasticity of sphincter muscles may provide a means by which a patient can
develop a bowel and bladder control program. The hemiplegic patient may
have enough muscle tone as a result of spasticity which will aid in learning to
walk again with a leg that cguld have potentially been flaccid or weak. An
increase in muscle tone due to spasticity may be a favorable source of stress
on bones in preventing breakdown of bone which would result if muscular
stresses are removed.
Problems can arise when spasticity becomes too severe. Some of the
negative effects which result may include: pain, impaired hygiene, joint
contracture, hydronephrosis and renal damage, pressure ulcer formation and
skin breakdown, and impaired activities of daily living and functional
activities. 13•14 Pain may result from severe and violent spasms. Hygiene of the
perineal area will be limited if adductors become tight and prevent proper
washing of that area. Joint"contracture will be a result of prolonged contracture
which leads to insufficient movement throughout the range of motion and
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results in contracture formation. 10 When excessive spasticity of the urinary
sphincter exists, it may cause reflux of urine and result in problems with the
renal system. Pressure sores and skin breakdown occur when there is an
inability to sufficiently relieve pressure. Impaired activities of daily living and
functional activities result when there is absence of voluntary control and
movement.
Physical therapists treating neurological patients will primarily be
interested in how motor function has been affected. After all, rehabilitation of
motor function is the area in which the physical therapist spends all of his or
her time.

Haley and Inaci014 contend that spasticity in upper motor neuron

syndromes influences motor dysfunction in three ways. First, it affects passive
movement and static postural alignments. Second, it affects voluntary
movement. Third, it may coexist with other upper motor neuron deficits and
may play an insignificant

ro!~

in regard to motor dysfunction. Earlier, we

examined specific examples of problems and benefits of spasticity. These are
clearly related to the influence that spasticity has on motor dysfunction. These
three factors involve the very areas addressed by physical therapy.
Assessment becomes necessary to evaluate whether spasticity is
interfering with movement and, if so, to what degree. When spasticity is too
severe and interrupts motor function, it becomes necessary to implement
management techniques in order to decrease the severity of the negative
effects. Ideally, intervention aims at making positive gains in motor function.
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By decreasing or negating spasticity and its effect upon motor function, it is
thought that motor movement will become less difficult.
Homberg 15 suggests that the rehabilitation program should be a multidisciplinary process involving goal setting and continual reassessments. He
suggests a rehabilitation process in spastic syndromes. The process involves
four steps: 1) Identify actual functional deficits; 2) Establish a plan to alleviate
deficits and exploit residual function; 3) Before considering drugs, exploit
residual abilities and/or physical therapy; 4) Do not use drugs without defining
clear goals for activities of daily living.
Although the author intended this system to evaluate the need for drug
therapy, it clearly is a useful system when considering any type of intervention.
It should be kept in mind that treatment should be planned based upon goals
and desired outcome. Treatment should not simply aim at eliminating
spasticity, but look at spasticity in terms of how it is affecting the individual's
level of function. The overall goal should be to maximize the individual's ability
to function in daily living.
There are a variety of approaches for the management of spasticity. The
physical therapist may be directly involved by using conservative physical
therapy techniques. These may include such things as range or motion,
therapeutic exercise, functional electrical stimulation, heat and cold modalities,
vibration, and orthoses. 13 Other techniques include seating, splinting, and
casting. 16 However, the use of conservative management alone may not be
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enough. It may be necessary to implement medical methods of managing
spasticity. Prescribing medical intervention is not within the scope of physical
therapy practice. However, the physical therapist and consequently the
physical therapy program will be directly affected by the medical treatment of
spasticity. Furthermore, conservative techniques and medical management
may be combined to create a spasticity management program customized to
the individual's needs. Barnes16 states that treatment should be based upon
establishment of specific functional goals which are based upon the
improvement of function, the prevention of complications, and the alleviation of
pain.

CHAPTER 3
PHARMACOLOGICAL TREATMENT
Pharmacological agents are frequently used for reducing spasticity. In
the literature 7,16-18 pharmacological agents are listed as a very relevant and
commonly used method 0.1 intervention for spasticity. Pharmacological agents
include oral and intrathecal administration of medications and local injections of
various agents.
Medications
Several articles7 ,16,18 list the three most common antispastic medications
as diazepam, dantrolene sodium, and baclofen. Though often used singly, they
may be used in various combinations. 16 This allows a cpmbination of effects
from several drugs in attempt to gain maximal benefits.
Diazepam, also known as Valium, has an affect both on the brain and on
the spinal cord. 7 · lt belongs to the family of benzodiazepines1•9

Taken orally,

diazepam acts to increase inhibitory activity of lower motor neurons by
facilitating transmission of GABA at GABAA-receptor sites. Common side
,

effects include drowsiness, dizziness, weakness, hypotension, fatigue, vertigo,
ataxia, and withdrawal. 7,16,18

10

11

A study of the effects of a low dose benzodiazepine (Clonazepam)
revealed that treatment with a low dose benzodiazepine was e,ffective in
reducing spasticity in children with cerebral palsy.17 Young and Delwaide18
state that Diazepam is a useful treatment approach in individuals with spinal
cord damage and sometimes for individuals with cerebral palsy. Penn 20 feels
that it is the second most effective drug for treating spasticity next to baclofen
and that the side effects limit its use, often before clinical relief of symptoms are
seen.
Dantrolene sodium is administered orally and has a direct effect on the
muscle tissue itself?·18 It interrupts muscle contraction by suppressing the
release of calcium from the sarcoplasmic reticulum/·20 thus interfering with the
sequence of steps involved in a muscle contraction.
Common side effects include drowsiness, dizziness, weakness, fatigue,
and diarrhea. 16 Barnes16 notes that there have been reports of hepatotoxicity
and that liver function should be closely monitored in those individuals receiving
dantrolene. Additionally, dantrolene sodium and its action on the muscle cause
mus9Je weakness?·2o Several authors·18.2o suggest that Dantrolene sodium may
only

be desirable for individuals who are not expected to make functional gains

due to:
, ,the effect of muscle weakness.

•

Young and Delwaide18 state that dantrolene may be helpful in reducing
spasticity regardless of where the lesion is located. This includes individuals
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with multiple sclerosis, spinal cord injury, cerebral palsy, and cerebrovascular
accident.
Baclofen may be administered oralll,16,20 or intrathecally.21-23 Baclofen
acts as an agonist to GABAs-receptors? Its action is to inhibit the release of
excitatory neurotransmitters and it primarily targets polysynaptic spinal
reflexes. 16 The main side effects include drowsiness, fatigue, and muscle
weakness which are usually dose-dependent effects. It has been suggested by
several authors16,2o that baclofen may be most effective for spasticity of spinal
origin.
Intrathecal baclofen is administered via an infusion pump which delivers
baclofen into the subarachnoid space. 21 The pump is implanted under the skin
on the lateral aspect of the abdomen. It is then hooked to a catheter in the
intrathecal space. Penn 20 explains the benefit of administering baclofen
intrathecally over administering it orally. He states that the dose of oral
baclofen required to relieve symptoms in individuals with severe spasticity will
often cause unwanted side effects. However, if delivered directly into the
subarachnoid space, the concentration is higher around the spinal cord while
remaining low around the brain. Thus, unwanted side effects can be avoided
while delivering adequate levels of baclofen to the spinal cord promoting its
effect on spasticity.
Several studies24',25 have shown the effectiveness of intrathecal baclofen
for treating spasticity in cerebral palsy and other causes of cerebral origin.
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These studies showed significant decreases in muscle tone after intrathecal
administration of baclofen. Confusion and drowsiness occurred in two of the
subjects of one study, but cleared two hours following the dose. 24 Intrathecal
baclofen may also be useful for long term treatment of multiple sclerosis or
spinal cord injury.21
Side effects from intrathecal baclofen are due to the side effects of the
drug itself. An overdose may lead to seizures, coma, respiratory problems, and
flaccidity.21 There may be technical difficulties with kinks, dislodging,
disconnections, or tears in the catheter. Additionally, infection at the site of the
pump or pump failure may occur.
There are many other medications which have been used to decrease
spasticity; however, they are not as common. Two recent examples include
tizanidine 7 and divalproex sodium~6 Tizanindine, an alph~-receptor agonist, is
thought to reduce the release of the excitatory neurotransmitter, aspartate. 7
However, it is currently not available in the United States. Divalproex sodium,
an antiepileptic agent, was shown to be an effective oral agent for improving
pain and spasticity in three out of four patients in a recent study.26
Local Injections
. .

Inclusive in this category are nerve blocks and other local injections.
Nerve blocks involve the injection of a nerve with phenol, alcohol, or a local
anaesthetic agent using a needle. 16 Nerve blocks decrease spasticity by
blocking nerve conduction through chemical neurolysis of nerve tissue.2728
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Barnes 16 states that it is preferable to block motor nerves rather than mixed
sensorimotor nerves. However, it is possible to inject either motor nerves or
. .

mixed sensorimotor nerves.

27

Nerves which are commonly blocked include:

obturator, sciatic, tibial, femoral, paravertebral, thoracodorsal,
musculocutaneous, median, and ulnar. 16.27
Gunduz, et al28 conducted a study in which peripheral nerve blocks were
used to treat spasticity in spinal cord injured patients. The results showed that
peripheral nerve blocks were effective in relieving spasticity, but only on a
temporary basis.
Keenan, et al 29 performed a study with percutaneous block of the
musculocutaneous nerve to control elbow flexor spasticity. The results revealed
that this method provides a reliable and tempqrary means for reducing
spasticity. The authors felt it would be especially helpful in those individuals
who have potential to improve neurologically.
Side effects of peripheral nerve blocks are minimal. Patients may
become anxious and need to undergo general anaesthesia or local anaesthetic
may be applied, however, will not be effective if thE:lre is a need to penetrate
more deeply.16
Botulinum-A toxin, an exotoxin produced by the bacterium Clostridium
Botulinum, is a new agent used for local intramuscular injections. 30 It is injected
directly into the muscle? The botulinum toxin blocks the presynaptic release of
acetylcholine causing a neuromuscular block.30 ·
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Snowet al,31 conducted a study with nine chronic multiple sclerosis
patients who were confined to a bed or wheelchair and were residents of a long
term care facility. The study involved injecting the botulinum toxin into spastic
adductors of the subjects to see if it would allow for easier nursing care. The
results of the study revealed that there were significant improvements in muscle
tone, frequency of spasm, and hygiene. No side effects were noted.
In a double-blind study testing the effectiveness of botulinum-A toxin to
manage dynamic equinus deformity associated with cerebral palsy, Koman and
associates32 reported improvement in the gait pattern of five out of six patients.
Although no significant side"effects were noted, soreness occurred at the site of
injection in three of six subjects. However, this side effect also occurred with
the placebo.

CHAPTER 4
DORSAL RHIZOTOMY
Dorsal rhizotomy, more commonly referred to as selective posterior
rhizotomy (SPR) or selective dorsal rhizotomy (SDR), is a neurosurgical
procedure that reduces spasticity and hyperactive stretch reflexes by cutting
through the sensory portion of selected posterior nerve rootlets in the
lumbosacral area. 33.34 They are most commonly performed on individuals with
cerebral palsy; however, they have sometimes been used for spasticity in
patients with myelomeningocele, multiple sclerosis; head injury and, spinal cord
injury.33
Surgery is performed 'with the patient under general anaesthesia and
begins with a laminectomy or laminotomy medial to the facet joint of L2-L s
vertebrae. The posterior nerve roots and rootlets from L2 through

~

are

identified and then stimulated electrically. Motor responses are monitored
visually, by palpation, and via electromyography (EMG). Abnormal responses
are considered to be: a duration sustained beyond the one second stimulus,
spread of contraction to other muscles not innervated by the rootlet which was
tested, and other irregular patterns of contraction. Those rootlets which present

16
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with abnormal responses are severed. All other rootlets are left intact. 34 ,35
Generally, 25% to 60% of the sensory rootlets are clipped. 35
Success of SPR relies heavily upon appropriate patient selection and a
commitment by the family and patient to participate in an aggressive
postoperative physical therapy program. 36 Patient selection should be
conducted by a team and may include the following disciplines: physical
therapist, occupational

~herapist,

social worker, pecjiatrician, neurophysiologist,

orthopaedic surgeon, and surgical neurologist. 36 Candidate selection is very
crucial because it attempts to rule out those who have motor impairments due
to dystonia, athetosis, ataxia, and abnormal reflex posturing. 5 Peacock and
Staudes list the following six factors for the selection process: 1) Confirm
diagnosis of CP; 2) Identify spasticity as a predominant interfering factor;
3) Rule out other forms of hypertonicity, such as rigidity and dystonia;
4) Evaluate range of motion (ROM) - osteotendinous deformities will not be
helped by rhizotomy; 5) Evaluate underlying strength and selective control;
6) Goals should be carefully· considered and discussed with patient and family
prior to surgery.
The overall goal of patient selection is to select those individuals who
have the potential to make some improvements from their present functional
level. 34-36 For example, a child who adducts severely during gait may have
eased gait after the spasticity in the adductors has decreased. However, a
child who does not have the potential to ambulate will not become ambulatory
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simply from undergoing the surgery. In contrast, however, a child who relies on
spasticity for movement may experience a decrease in function when that is
taken away. Surgery can help to improve the quality and performance of skills
that the child can already do and will heavily depend upon strength, motor
control, absence of osteotendinous deformities, and other factors which exist
prior to surgery.35 Selective posterior rhizotomy may be favorable to reduce
severe spasticity in individuals to ease positioning and to inhibit formation of
deformities. 37 Several author~5,36 list characteristics desirable for SPR
candidates (Table 1).
Contraindications for SPR include weakness of antigravity muscles,
weakness or hypotonia of the trunk, major non-spastic motor disorders
(athetosis, ataxia, rigidity, dystonia), severe spinal deformity or scoliosis,
multiple fixed contractures, multiple prior extremity surgery (with exception), and
mentally retarded (with exception).35,36 Children who have severe spastic
quadriplegia may be unrealistic candidates because all rootlets which are
stimulated react abnormally and a partial rhizotomy of 60% to 70% of all
rootlets may only provide minimal long term relief.36
Boscarino and associates38 examined the effects of selective dorsal
rhizotomy on the gait pattern of children who had cerebral palsy. Nineteen
children who were ambulatory (both independent and dependent upon a
walking aid) underwent preoperative and postoperative (one year) gait analyses
that included assessment ·of range of motion (ROM), muscle tone, motion
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Table 1. Desirable characteristics of selective posterior rhizotomy candidates.

Born prematurely
Spastic diplegic
Age 2-10 years
Progressive motor development history
Evidence of selective motor control
Good trunk control
Good underlying strength
Potential ambulator (preferably independent ambulator)
Absence of fixed contractures
Minimal or no previous lower extremity surgery
Minimal or no osteotendinous changes
Absence of postural hypotonia
Motivation/commitment to postoperative physical therapy
Intelligence (10 > 80) for effective therapy participation
Family support
Possibility of eased nursing care
Prevent/stop severe joint contractures and subluxations

20

analysis in three dimensions, and electromyography during gait. Examiners noted
improvements in passive ROM, lower extremitY spasticity, and sagittal plane hip,
knee, and ankle motion. Additionally, on the average there was a greater amount
of plantargrade foot position during stance phase. No changes were noted in
coronal plane motion of the hip and pelvis. An increase in anterior pelvic tilt
position in the independent .ambulators was noted as the only negative change.
Park and colleagues39 examined how dorsal rhizotomy affects lateral hip
migration in children with spastic diplegia. A migration percentage was calculated
through preoperative and postoperative radiographs of the hips of 67 children. All
children were between the ages of two and eleven at the time of surgery. Followup periods ranged from six to 46 months. The migration percentages remained
unchanged in 75%, decreased in 17%, and increased in 7% of all patients. The
examiners felt that results suggested that lateral hip migration is halted by selective
dorsal rhizotomy in the great majority of cases of children with spastic diplegia.
McLaughlin and associates40 conducted an observational study of 34
consecutive children who received SDR at their facility. Twenty-four of the children
had spastic diplegia and ten had spastic quadriplegia. All children received one
month of postoperative physical therapy and received physical therapy
prescriptions in their own communities for one year.

They were assessed

preoperatively and one year after surgery. The following tools were used for
assessment: Ashworth scale, which is a sca1e for grading spasticity; range of
motion; deep tendon reflex responses; and the Gross Motor Function Measure,

21
which measures gross motor skills and changes in children with cerebral palsy.
Results revealed a great deal of variability with each individual; however, often
spasticity in the lower extremities was reduced and functional capabilities improved
with SDR. The authors felt it necessary to conduct further studies to determine the
effectiveness of SDR.
None of the studies38-40 listed any major complications as a result of surgery.
McLaughlin, et al40 report some mild complications .in a small number of children
postsurgically, such as mild transient paresthesias lasting two weeks or less,
dysesthesias for more than two months, postoperative bladder incontinence as a
result of urethrities which resolved with antibiotic treatment. Additionally, some had
reported back or hip pain for two weeks to six to nine months, intermittent mild
back pain for approximately six months. Peacock and Staudes list the possibility
of the following postoperative problems: hypersensitivity of the feet and legs and
flexor spasms early following surgery; crouched posture; poor tibial control; ankle
valgus; weakness of trunk, hip, quadriceps, calves and dorsiflexors. Yet other
authors41 •42 list these possible temporary complications: kyphosis, wound infection
or meningitis, cerebral spinal fluid leak, motor paralysis, transient or permanent
sensory loss, bladder or bowel dysfunction, valgus or varus foot position, transient
muscle weakness and hypotonia, risk from anaesthesia.

CHAPTER 5
CONCLUSION
Spasticity is a very complex and intriguing phenomenon. It is an entity with
which physical therapists are quite frequently faced. Although it may be beneficial
in some cases, it is more commonly a major source of disability to those who have
sustained an insult to the central nervous system. When it becomes too severe,
it can cause multiple complications which interfere with activities of daily living. It
is for this reason that management of spasticity becomes necessary.
Physical therapists will frequently be directly involved in the treatment of
individuals with spasticity, including approaches to decrease unwanted spasticity.
However, often this will not suffice and medical management will become
necessary.
Medical management may include the use of pharmacological agents or
neurosurgical techniques, such as selective dorsal rhizotomy. Pharmacological
treatment may include medications or local inje.ctions with various agents. These
methods are temporary and the effects only last for short periods unless use is
continued and/or repeated. The commonly used oral medications are diazepam,
dantrolene sodium, and baclofen. Baclofen may be administered orally as well as
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intrathecally.

Local treatment includes injections with phenol, alcohol, a local

anaesthetic agents, or the botulinum-A toxin.
Dorsal rhizotomy may be an option for spasticity management if other
methods have proven ineffective.

Its effects are permanent and irreversible

because nerve rootlets are actually severed.
The particular method of management will depend upon the severity of
spasticity and the goals to be achieved with reduction. The pros and cons of each
method will need to be considered carefully in order to select the most appropriate
treatment.

Physical therapists may not prescribe pharmacological or surgical

treatments; however, they may be a member of a multidisciplinary team which
assesses and sets goals for patients. The physical therapist serves a vital role by
contributing information as to whether or not an individual could improve
functionally if spasticity were reduced.
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